Atara Biotherapeutics Q2 EPS $(0.68) Misses $(0.67) Estimate, Sales $957.00K Miss $3.77M Estimate
Portfolio Pulse from mahesh@benzinga.com
Atara Biotherapeutics reported Q2 losses of $(0.68) per share, missing the analyst consensus estimate of $(0.67) by 1.49%. This is a 119.35% decrease from the same period last year. The company also reported quarterly sales of $957.00K, missing the analyst consensus estimate of $3.77M by 74.62%. This is a 98.14% decrease from the same period last year.
August 08, 2023 | 8:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics reported lower than expected Q2 earnings and sales, which could negatively impact its stock price.
Atara Biotherapeutics reported a larger than expected loss and lower than expected sales for Q2. This could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100